KRAS and cancer: Spikes in cfDNA or changes in the KRAS mutation status of ctDNA may be predictive of the success of treatment in resectable PDAC patients undergoing neoadjuvant therapy and are associated with effective anti-cancer treatments resulting in cellular material dissemination.